OPDIVO vs PADCEV

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 19, 2026·How we rate

Possible drug interaction. OPDIVO and PADCEV are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	OPDIVO	PADCEV
Rating	72/100	72/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	NIVOLUMAB	ENFORTUMAB VEDOTIN-EJFV
Manufacturer	Bristol Myers Squibb	Astellas
Dosage forms	Injectable	Injectable
Drug class	Programmed Death Receptor-1 Blocking Antibody	—
Boxed warning	None	Boxed warning
Treats	Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma	Urinary Bladder Neoplasms

opdivo padcev

Rating

72/100

Pharmacy pays

—

Type

Active ingredient

NIVOLUMAB

ENFORTUMAB VEDOTIN-EJFV

Manufacturer

Bristol Myers Squibb

Astellas

Dosage forms

Injectable

Drug class

Programmed Death Receptor-1 Blocking Antibody

—

Boxed warning

None

Boxed warning

Treats

Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma

Urinary Bladder Neoplasms

Frequently asked questions

Which is better-rated, Opdivo or Padcev?

Opdivo and Padcev are tied at 3.6 out of 5 by our independent rating.

What is the difference between Opdivo and Padcev?

Opdivo contains Nivolumab, while Padcev contains Enfortumab Vedotin-Ejfv — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.